APP-FUBINACA
APP-FUBINACA[edit]
APP-FUBINACA is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of a class of compounds that are often used in the production of designer drugs and are sometimes found in products marketed as "synthetic cannabis".
Chemical Properties[edit]
APP-FUBINACA is chemically classified as an indazole-based synthetic cannabinoid. It is structurally related to other synthetic cannabinoids such as AB-FUBINACA and ADB-FUBINACA. The compound is known for its high affinity and efficacy at the CB1 receptor, which is primarily responsible for the psychoactive effects associated with cannabinoids.
Pharmacology[edit]
APP-FUBINACA acts as a full agonist at the CB1 receptor and CB2 receptor, with a higher affinity for the CB1 receptor. This interaction leads to the activation of the endocannabinoid system, resulting in effects that mimic those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Effects[edit]
The effects of APP-FUBINACA can include euphoria, relaxation, altered perception, and increased appetite. However, due to its potency, it can also cause adverse effects such as anxiety, paranoia, tachycardia, and in severe cases, psychosis or seizures.
Legal Status[edit]
Due to its potential for abuse and lack of medical use, APP-FUBINACA is classified as a controlled substance in many countries. It is often included in legislation targeting synthetic cannabinoids and other new psychoactive substances (NPS).
Synthesis[edit]
The synthesis of APP-FUBINACA involves the reaction of an indazole core with a fluorobenzyl group and a carboxamide moiety. The process requires specialized knowledge in organic chemistry and access to controlled precursors.
Health Risks[edit]
The use of APP-FUBINACA is associated with significant health risks. Overdose can lead to severe cardiovascular and neurological complications. Long-term use may result in addiction and cognitive impairment.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
